ADICET BIO INC (ACET)

Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Announces Appointment of Katie Peng to the Board of Directors

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Thursday Sector Laggards: Advertising, Biotechnology Stocks

JMP downgrades Adicet to market perform, citing study delay (ACET)

JMP Securities downgraded Adicet Bio (ACET) to market perform and removed its price target of $19, citing uncertainty about the start date for a pivotal study. Read more here.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on Tuesday morning!

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Oversold Conditions For Adicet Bio (ACET)

Adicet stock falls as JPMorgan downgrades (NASDAQ:ACET)

JPMorgan downgraded Adicet Bio (ACET) Thursday, citing a lack of near-term stock moving events, sending its ~5% lower in the pre-market. Read more here.

Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference